Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation

Stefano Barco; Michiel Coppens; Erik-Jan van den Dool; Daan van de Kerkhof; An K. Stroobants; Saskia Middeldorp

doi:10.1160/TH14-03-0214

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(04): 836-838
DOI: 10.1160/TH14-03-0214

Letters to the Editor

Schattauer GmbH

Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation

Stefano Barco

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

²Department of Internal Medicine, IRCCS Policlinico “San Matteo” Foundation, University of Pavia, Italy

,

Michiel Coppens

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

,

Erik-Jan van den Dool

³Laboratory for General Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands

,

Daan van de Kerkhof

⁴Clinical Laboratory, Catharina Hospital, Eindhoven, The Netherlands

,

An K. Stroobants

³Laboratory for General Clinical Chemistry, Academic Medical Center, Amsterdam, The Netherlands

,

Saskia Middeldorp

¹Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands

› Author Affiliations

Abstract

Full Text

References

References
1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2 Boehringer-Ingelheim. Pradax - Product Monograph. 2012; 1-57. Available from: boehringer-ingelheim.ca/content/dam/internetopu/ca_EN/documents/humanhealth/prod-uct_monograph/Pradax-pm.pdf
3 Boehringer-Ingelheim. Highlight of prescribing information. 2014; 1-24. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccessViewServlet.ser?docBase=renetnt&folder-Path=/PrescribingInformation/PIs/Pradaxa/Pradaxa.pdf .
4 Reilly PA, Lehr T, Haertter S. et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63: 321-328.
5 EMA. Pradaxa - Summary of product characteristics. 1-146. Available from: http://www.ema.eu ropa.eu/docs/en_GB/document_libraryEPAR_-_Product_Information/human/000829/WC500041059.pdf
6 Chang C, Bahadduri PM, Polli JE. et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006; 34: 1976-1984.
7 Providência R, Albenque J-P, Combes S. et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014; 100: 324-335.
8 Lehr T, Haertter S, Liesenfeld K-H. et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012; 52: 1373-1378.
9 Härtter S, Sennewald R, Nehmiz G. et al. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 2013; 75: 1053-1062.